Prevalence of Antiphospholipid Antibodies Among Women With Preeclampsia

Overview

The purpose of this study is to determine the prevalence of positive antiphospholipid antibodies among women with preeclampsia and to determine the effect of antiphospholipid antibodies on the severity of preeclampsia and the obstetric outcomes

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Cross-Sectional
  • Study Primary Completion Date: December 31, 2019

Detailed Description

For all women included in the study, blood samples will be tested for anticardiolipin antibodies and lupus anticoagulant. The clinical details of all women will be collected by reviewing their hospital and prenatal records. The following clinical characteristics will be evaluated: maternal age, previous gestations, parity, past or family history of preeclampsia, gestational age at the onset of preeclampsia, gestational age at delivery and birth weight. The following pregnancy and delivery complications will be assessed: placental insufficiency, intrauterine growth restriction, fetal loss (stillbirth) and early neonatal death.

Interventions

  • Other: Testing for antiphospholipid antibodies
    • Blood samples will be tested for anticardiolipin antibodies and lupus anticoagulant

Arms, Groups and Cohorts

  • Pregnant women with preeclampsia
    • Testing for antiphospholipid antibodies (anticardiolipin antibodies and lupus anticoagulant) will be performed in pregnant women with preeclampsia.

Clinical Trial Outcome Measures

Primary Measures

  • Rate of positive antiphospholipid antibodies
    • Time Frame: 20 weeks to 42 weeks gestational age
    • Number of women having positive antiphospholipid antibodies per total number of women

Participating in This Clinical Trial

Inclusion Criteria

  • Pregnant women with preeclampsia. Exclusion Criteria:

  • Women with systemic autoimmune disease. – Women with active thromboembolic disorders. – Women with history of previous thromboembolic disorders.

Gender Eligibility: Female

Minimum Age: 20 Years

Maximum Age: 35 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Mohamed Sayed Abdelhafez
  • Provider of Information About this Clinical Study
    • Sponsor-Investigator: Mohamed Sayed Abdelhafez, Dr – Mansoura University
  • Overall Official(s)
    • Hanaa M El-Shafiey, Principal Investigator, Mansoura University
    • Mohamed S Abdelhafez, Dr, Study Director, Mansoura University
    • Alaa El-Din M El-Gohary, Dr, Study Director, Mansoura University
    • El-Said M Abd El-Hady, Prof, Study Chair, Mansoura University

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.